Latest news
Front-row seats to our progress
Looking for the latest news about our journey?
Shifting the Paradigm
in Cell Therapy
Our mission is to bring cell therapies to more patients to save lives. With capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, we are committed to challenging the status quo and delivering results for cancer patients.
High unmet medical need
Only 25%-30%1 of eligible patients currently receive CAR-T therapy due
to current centralized manufacturing constraints
Limited capacity
Complex logistics
Restricted access
Decentralized Cell Therapy Manufacturing
Delivering fresh, stem-like early memory CAR-T therapy in median 7 days vein-to-vein
At Galapagos, we are pioneering the future of cell therapy with a scalable, decentralized, and fast approach – delivering fresh, fit, stem-like, early memory cell therapy within a median vein-to-vein time of just seven days.
Our high-yielding discovery engine drives the development of multi-targeting, next-generation cell therapies, expanding the possibilities for patients in need.
With our decentralized manufacturing approach, we’re aiming
to overcome the hurdles currently stopping patients from receiving treatment
Innovative and differentiating
Our Decentralized Manufacturing Platform
The platform consists of an end-to-end xCellit® workflow management and monitoring software system, a decentralized, functionally closed, automated manufacturing platform for cell therapies (using Lonza’s Cocoon®) and a proprietary quality control testing and release strategy. No cryopreservation of cells is needed.
xCellitTM
A cloud-based platform that covers the entire workflow and allows real-time monitoring
Automated manufacturing platform
A next-generation automated and closed manufacturing system enables point-of-care production using Lonza’s Cocoon®
Innovative QC testing and release strategy
A proprietary quality control testing
and release strategy
Delivery of fresh, fit, stem-like, early memory cell therapy
within a median vein-to-vein time of just seven days
Discover Our Pipeline
Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class medicines.
1Kourelis T., Bansal R., Patel K.K., et al. Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access. J Clin Oncol. 2022;40(16_suppl):e20021. | Hoffman M.S., Hunter B.D., Cobb P.W., Varela J.C., Munoz J. Overcoming barriers to referral for chimeric antigen receptor T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma. Transplant Cell Ther. 2023;29(7):440-448. | Mikhael J., Fowler J., Shah N. Chimeric antigen receptor T-cell therapies: Barriers and solutions to access. JCO Oncol Pract. 2022;18(1).
²GMP production at a compliant manufacturing facility located at the clinic premises or in close proximity to the clinic
The Cocoon® Platform is a registered trademark of Lonza Group AG
Pioneering for patients
Work at Galapagos
This is your call for purpose. Discover it today!
Partnerships
Work with Galapagos
Let’s pioneer for patients,
together!